应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
MRSN Mersana Therapeutics Inc.
交易中 12-08 12:43:24 EST
27.93
+0.16
+0.56%
最高
28.10
最低
27.80
成交量
1.83万
今开
28.03
昨收
27.78
日振幅
1.08%
总市值
1.40亿
流通市值
1.05亿
总股本
499.88万
成交额
51.25万
换手率
0.49%
流通股本
375.34万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Mersana Therapeutics 第三季度每股亏损1.51美元
投资观察 · 11-20
Mersana Therapeutics 第三季度每股亏损1.51美元
Mersana Therapeutics Inc:Leerink Partners将评级从“跑赢大盘”下调至“市场表现”,目标价由44美元下调至29美元
美股速递 · 11-13
Mersana Therapeutics Inc:Leerink Partners将评级从“跑赢大盘”下调至“市场表现”,目标价由44美元下调至29美元
Mersana Therapeutics Inc.:Truist证券将评级从买入下调至持有;目标价格从36美元下调至30.75美元
美股速递 · 11-13
Mersana Therapeutics Inc.:Truist证券将评级从买入下调至持有;目标价格从36美元下调至30.75美元
Mersana Therapeutics Inc:Wedbush将评级从优于大盘下调至中性;目标价从13美元上调至27.25美元
美股速递 · 11-13
Mersana Therapeutics Inc:Wedbush将评级从优于大盘下调至中性;目标价从13美元上调至27.25美元
Mersana Therapeutics股价在盘前上涨206%,因公司将被Day One Biopharmaceuticals收购
美股速递 · 11-13
Mersana Therapeutics股价在盘前上涨206%,因公司将被Day One Biopharmaceuticals收购
Mersana Therapeutics, Inc.盘中异动 临近收盘快速下挫5.40%报6.66美元
市场透视 · 08-07
Mersana Therapeutics, Inc.盘中异动 临近收盘快速下挫5.40%报6.66美元
Mersana Therapeutics, Inc.盘中异动 早盘股价大跌6.36%报7.21美元
市场透视 · 07-28
Mersana Therapeutics, Inc.盘中异动 早盘股价大跌6.36%报7.21美元
Mersana Therapeutics, Inc.盘中异动 大幅上涨5.31%报0.343美元
市场透视 · 07-17
Mersana Therapeutics, Inc.盘中异动 大幅上涨5.31%报0.343美元
Mersana Therapeutics, Inc.盘中异动 快速上涨5.29%
市场透视 · 07-03
Mersana Therapeutics, Inc.盘中异动 快速上涨5.29%
Mersana Therapeutics, Inc.盘中异动 股价大跌5.29%报0.516美元
市场透视 · 03-11
Mersana Therapeutics, Inc.盘中异动 股价大跌5.29%报0.516美元
Mersana Therapeutics, Inc.2024财年实现净利润-69.19百万美元,同比增加59.77%
市场透视 · 03-09
Mersana Therapeutics, Inc.2024财年实现净利润-69.19百万美元,同比增加59.77%
Mersana Therapeutics, Inc.盘中异动 早盘急速下挫5.43%报0.495美元
市场透视 · 03-03
Mersana Therapeutics, Inc.盘中异动 早盘急速下挫5.43%报0.495美元
Mersana Therapeutics(MRSN.US):2024年Q4财报实现营收1636.1万美元,前值为1070.1万美元,预期值为771万美元;每股收益为-0.11美元,前值为-0.16美元,预期值为-0.15美元。
金融界 · 03-03
Mersana Therapeutics(MRSN.US):2024年Q4财报实现营收1636.1万美元,前值为1070.1万美元,预期值为771万美元;每股收益为-0.11美元,前值为-0.16美元,预期值为-0.15美元。
Mersana Therapeutics第四季度每股收益$(0.11),超出预期$(0.15);销售额$1636万,超出预期$771万
财报速递 · 03-03
Mersana Therapeutics第四季度每股收益$(0.11),超出预期$(0.15);销售额$1636万,超出预期$771万
Mersana Therapeutics, Inc.盘中异动 下午盘大幅下跌5.09%
市场透视 · 02-28
Mersana Therapeutics, Inc.盘中异动 下午盘大幅下跌5.09%
Mersana Therapeutics, Inc.盘中异动 股价大跌5.32%
市场透视 · 02-25
Mersana Therapeutics, Inc.盘中异动 股价大跌5.32%
Mersana Therapeutics, Inc.盘中异动 大幅拉升5.03%报0.560美元
市场透视 · 02-25
Mersana Therapeutics, Inc.盘中异动 大幅拉升5.03%报0.560美元
Mersana Therapeutics, Inc.盘中异动 早盘快速拉升5.45%
市场透视 · 02-18
Mersana Therapeutics, Inc.盘中异动 早盘快速拉升5.45%
Mersana Therapeutics, Inc.盘中异动 急速拉升5.02%
市场透视 · 02-14
Mersana Therapeutics, Inc.盘中异动 急速拉升5.02%
Mersana Therapeutics, Inc.盘中异动 股价大跌5.01%报0.613美元
市场透视 · 02-13
Mersana Therapeutics, Inc.盘中异动 股价大跌5.01%报0.613美元
加载更多
公司概况
公司名称:
Mersana Therapeutics Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Mersana Therapeutics, Inc.于2002年2月以名称Nanopharma Corp.在特拉华州注册成立。2005年11月,他们更名为Mersana Therapeutics,Inc.。该公司是一家临床阶段的生物制药公司,专注于开发抗体药物偶联物,或ADC,为有重大未满足需求的癌症患者提供具有临床意义的益处。该公司利用ADC领域20年的行业学习,开发专有技术,使设计ADC相对于现有ADC疗法具有更好的疗效、安全性和耐受性。此外,公司与Takeda Pharmaceutical Company Limited或武田建立战略合作关系,据此公司获得了XMT-1522在美国和加拿大以外地区的权利。该公司还与武田和默沙东 KGaA建立了战略研发合作伙伴关系,用于针对合作伙伴基于其Dolaflexin平台选择的有限数量的目标开发和商业化额外的ADC候选产品。
发行价格:
--
{"stockData":{"symbol":"MRSN","market":"US","secType":"STK","nameCN":"Mersana Therapeutics Inc.","latestPrice":27.93,"timestamp":1765215774049,"preClose":27.775,"halted":0,"volume":18340,"delay":0,"floatShares":3753400,"shares":4998750,"eps":-14.086146,"marketStatus":"交易中","change":0.155,"latestTime":"12-08 12:43:24 EST","open":28.03,"high":28.1,"low":27.8,"amount":512512.62048,"amplitude":0.010801,"askPrice":28.05,"askSize":23,"bidPrice":27.93,"bidSize":101,"shortable":3,"etf":0,"ttmEps":-14.086146,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765227600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1498622400000,"exchange":"NASDAQ","adjPreClose":27.775,"preHourTrading":{"tag":"盘前","latestPrice":27.51,"preClose":27.775,"latestTime":"08:44 EST","volume":20,"amount":550.1327200000001,"timestamp":1765201479796},"postHourTrading":{"tag":"盘后","latestPrice":27.775,"preClose":27.775,"latestTime":"19:26 EST","volume":106,"amount":2953.35,"timestamp":1764980800233},"volumeRatio":0.75371,"impliedVol":0.2446,"impliedVolPercentile":0.1911},"requestUrl":"/m/hq/s/MRSN","defaultTab":"news","newsList":[{"id":"1197173029","title":"Mersana Therapeutics 第三季度每股亏损1.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197173029","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197173029?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:48","pubTimestamp":1763574538,"startTime":"0","endTime":"0","summary":"11月14日——Mersana Therapeutics 第三季度的合作收入为1100.9万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN","BK4563","BK4139"],"gpt_icon":0},{"id":"1169872506","title":"Mersana Therapeutics Inc:Leerink Partners将评级从“跑赢大盘”下调至“市场表现”,目标价由44美元下调至29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169872506","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169872506?lang=zh_cn&edition=full","pubTime":"2025-11-13 23:52","pubTimestamp":1763049131,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics Inc:Leerink Partners将评级从“跑赢大盘”下调至“市场表现”,目标价由44美元下调至29美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN","BK4139","BK4563"],"gpt_icon":0},{"id":"1161290878","title":"Mersana Therapeutics Inc.:Truist证券将评级从买入下调至持有;目标价格从36美元下调至30.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161290878","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161290878?lang=zh_cn&edition=full","pubTime":"2025-11-13 23:28","pubTimestamp":1763047694,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics Inc.:Truist证券将评级从买入下调至持有;目标价格从36美元下调至30.75美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","MRSN","BK4139"],"gpt_icon":0},{"id":"1190793041","title":"Mersana Therapeutics Inc:Wedbush将评级从优于大盘下调至中性;目标价从13美元上调至27.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190793041","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190793041?lang=zh_cn&edition=full","pubTime":"2025-11-13 20:50","pubTimestamp":1763038217,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics Inc:Wedbush将评级从优于大盘下调至中性;目标价从13美元上调至27.25美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","MRSN","BK4139"],"gpt_icon":0},{"id":"1168933249","title":"Mersana Therapeutics股价在盘前上涨206%,因公司将被Day One Biopharmaceuticals收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1168933249","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168933249?lang=zh_cn&edition=full","pubTime":"2025-11-13 19:22","pubTimestamp":1763032922,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics股价在盘前上涨206%,因公司将被Day One Biopharmaceuticals收购。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MRSN","BK4563"],"gpt_icon":0},{"id":"2557304159","title":"Mersana Therapeutics, Inc.盘中异动 临近收盘快速下挫5.40%报6.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557304159","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557304159?lang=zh_cn&edition=full","pubTime":"2025-08-07 03:52","pubTimestamp":1754509944,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日03时52分,Mersana Therapeutics, Inc.股票出现异动,股价急速下跌5.40%。Mersana Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.18%。Mersana Therapeutics, Inc.公司简介:梅莎娜制药有限公司是一家临床阶段的生物制药公司,专注于开发抗体-药物偶联物 ,为需求未得到满足的癌症患者提供具有临床意义的益处。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807035224a47945eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807035224a47945eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4539","BK4563","BK4007","MRSN"],"gpt_icon":0},{"id":"2554772463","title":"Mersana Therapeutics, Inc.盘中异动 早盘股价大跌6.36%报7.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554772463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554772463?lang=zh_cn&edition=full","pubTime":"2025-07-28 21:32","pubTimestamp":1753709570,"startTime":"0","endTime":"0","summary":"北京时间2025年07月28日21时32分,Mersana Therapeutics, Inc.股票出现异动,股价大幅跳水6.36%。Mersana Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.15%。Mersana Therapeutics, Inc.公司简介:梅莎娜制药有限公司是一家临床阶段的生物制药公司,专注于开发抗体-药物偶联物 ,为需求未得到满足的癌症患者提供具有临床意义的益处。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728213250a6c615f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728213250a6c615f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4007","MRSN","BK4139","BK4563","LENZ"],"gpt_icon":0},{"id":"2552912494","title":"Mersana Therapeutics, Inc.盘中异动 大幅上涨5.31%报0.343美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552912494","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552912494?lang=zh_cn&edition=full","pubTime":"2025-07-17 00:11","pubTimestamp":1752682278,"startTime":"0","endTime":"0","summary":"北京时间2025年07月17日00时11分,Mersana Therapeutics, Inc.股票出现波动,股价快速上涨5.31%。Mersana Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.37%。Mersana Therapeutics, Inc.公司简介:梅莎娜制药有限公司是一家临床阶段的生物制药公司,专注于开发抗体-药物偶联物 ,为需求未得到满足的癌症患者提供具有临床意义的益处。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071700111995450c91&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071700111995450c91&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","MRSN","BK4007","LENZ","BK4139","BK4539"],"gpt_icon":0},{"id":"2548388751","title":"Mersana Therapeutics, Inc.盘中异动 快速上涨5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548388751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548388751?lang=zh_cn&edition=full","pubTime":"2025-07-03 22:28","pubTimestamp":1751552939,"startTime":"0","endTime":"0","summary":"北京时间2025年07月03日22时28分,Mersana Therapeutics, Inc.股票出现波动,股价大幅上涨5.29%。Mersana Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.27%。Mersana Therapeutics, Inc.公司简介:梅莎娜制药有限公司是一家临床阶段的生物制药公司,专注于开发抗体-药物偶联物 ,为需求未得到满足的癌症患者提供具有临床意义的益处。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507032228599798b84e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507032228599798b84e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MRSN","BK4139","LENZ","BK4563","BK4007","BK4539"],"gpt_icon":0},{"id":"2518920945","title":"Mersana Therapeutics, Inc.盘中异动 股价大跌5.29%报0.516美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518920945","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518920945?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:31","pubTimestamp":1741631511,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时31分,Mersana Therapeutics, Inc.股票出现异动,股价快速跳水5.29%。Mersana Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.64%。Mersana Therapeutics, Inc.公司简介:梅莎娜制药有限公司是一家临床阶段的生物制药公司,利用其差异化和专有的 ADC 平台来开发具有更高耐受性和更多机会为患者带来有意义的临床益处的靶向药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311023151abf36a9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311023151abf36a9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MRSN","LENZ","BK4139","BK4563"],"gpt_icon":0},{"id":"2518244098","title":"Mersana Therapeutics, Inc.2024财年实现净利润-69.19百万美元,同比增加59.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518244098","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518244098?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449671,"startTime":"0","endTime":"0","summary":"3月9日,Mersana Therapeutics, Inc.公布财报,公告显示公司2024财年净利润为-69.19百万美元,同比增加59.77%;其中营业收入为40.50百万美元,同比增加9.88%,每股基本收益为-0.56美元。从资产负债表来看,Mersana Therapeutics, Inc.总负债1.54亿美元,其中短期债务16.40百万美元,资产负债比为0.95,流动比率为0.03。机构评级:截至2025年3月9日,当前有7家机构对Mersana Therapeutics, Inc.目标价做出预测,其中目标均价为4.71美元,其中最低目标价为1.00美元,最高目标价为9.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000233abef9846&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000233abef9846&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MRSN","LENZ"],"gpt_icon":0},{"id":"2516637305","title":"Mersana Therapeutics, Inc.盘中异动 早盘急速下挫5.43%报0.495美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637305","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516637305?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:35","pubTimestamp":1741012524,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时35分,Mersana Therapeutics, Inc.股票出现异动,股价大幅下挫5.43%。Mersana Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.27%。Mersana Therapeutics, Inc.公司简介:梅莎娜制药有限公司是一家临床阶段的生物制药公司,利用其差异化和专有的 ADC 平台来开发具有更高耐受性和更多机会为患者带来有意义的临床益处的靶向药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223524989a1072&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223524989a1072&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","MRSN","BK4563"],"gpt_icon":0},{"id":"2516805356","title":"Mersana Therapeutics(MRSN.US):2024年Q4财报实现营收1636.1万美元,前值为1070.1万美元,预期值为771万美元;每股收益为-0.11美元,前值为-0.16美元,预期值为-0.15美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516805356","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516805356?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:13","pubTimestamp":1741003983,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics(MRSN.US):2024年Q4财报实现营收1636.1万美元,前值为1070.1万美元,预期值为771万美元;每股收益为-0.11美元,前值为-0.16美元,预期值为-0.15美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03201348492141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","MRSN"],"gpt_icon":0},{"id":"1181244901","title":"Mersana Therapeutics第四季度每股收益$(0.11),超出预期$(0.15);销售额$1636万,超出预期$771万","url":"https://stock-news.laohu8.com/highlight/detail?id=1181244901","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181244901?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:06","pubTimestamp":1741003600,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics 报告季度每股亏损$,比分析师一致预期的$高出26.67%。这比去年同期的每股亏损$增长了31.25%。以上内容来自Benzinga Earnings专栏,原文如下:Mersana $Therapeutics$ reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 26.67 percent. This is a 31.25 percent increase over losses of $ per share from the same period last year. The company reported quarterly sales of $16.36 million which beat the analyst consensus estimate of $7.71 million by 112.20 percent. This is a 52.89 percent increase over s","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","MRSN"],"gpt_icon":0},{"id":"2514336335","title":"Mersana Therapeutics, Inc.盘中异动 下午盘大幅下跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514336335","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514336335?lang=zh_cn&edition=full","pubTime":"2025-02-28 02:06","pubTimestamp":1740679573,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日02时06分,Mersana Therapeutics, Inc.股票出现波动,股价大幅下挫5.09%。Mersana Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.37%。Mersana Therapeutics, Inc.公司简介:梅莎娜制药有限公司是一家临床阶段的生物制药公司,利用其差异化和专有的 ADC 平台来开发具有更高耐受性和更多机会为患者带来有意义的临床益处的靶向药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228020613989538f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228020613989538f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","LENZ","BK4139","MRSN"],"gpt_icon":0},{"id":"2514016572","title":"Mersana Therapeutics, Inc.盘中异动 股价大跌5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514016572","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514016572?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:36","pubTimestamp":1740497803,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时36分,Mersana Therapeutics, Inc.股票出现波动,股价快速下跌5.32%。Mersana Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.86%。Mersana Therapeutics, Inc.公司简介:梅莎娜制药有限公司是一家临床阶段的生物制药公司,利用其差异化和专有的 ADC 平台来开发具有更高耐受性和更多机会为患者带来有意义的临床益处的靶向药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022523364398925b50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022523364398925b50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4563","MRSN"],"gpt_icon":0},{"id":"2514771718","title":"Mersana Therapeutics, Inc.盘中异动 大幅拉升5.03%报0.560美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514771718","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514771718?lang=zh_cn&edition=full","pubTime":"2025-02-25 01:44","pubTimestamp":1740419070,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日01时44分,Mersana Therapeutics, Inc.股票出现波动,股价大幅拉升5.03%。Mersana Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.19%。Mersana Therapeutics, Inc.公司简介:梅莎娜制药有限公司是一家临床阶段的生物制药公司,利用其差异化和专有的 ADC 平台来开发具有更高耐受性和更多机会为患者带来有意义的临床益处的靶向药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022501443098911e8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022501443098911e8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4563","MRSN"],"gpt_icon":0},{"id":"2512165164","title":"Mersana Therapeutics, Inc.盘中异动 早盘快速拉升5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165164","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512165164?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:31","pubTimestamp":1739889106,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时31分,Mersana Therapeutics, Inc.股票出现异动,股价快速上涨5.45%。Mersana Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.23%。Mersana Therapeutics, Inc.公司简介:梅莎娜制药有限公司是一家临床阶段的生物制药公司,利用其差异化和专有的 ADC 平台来开发具有更高耐受性和更多机会为患者带来有意义的临床益处的靶向药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223146a24aac8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223146a24aac8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4563","MRSN"],"gpt_icon":0},{"id":"2511962066","title":"Mersana Therapeutics, Inc.盘中异动 急速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511962066","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511962066?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:46","pubTimestamp":1739544416,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时46分,Mersana Therapeutics, Inc.股票出现波动,股价大幅拉升5.02%。Mersana Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.28%。Mersana Therapeutics, Inc.公司简介:梅莎娜制药有限公司是一家临床阶段的生物制药公司,利用其差异化和专有的 ADC 平台来开发具有更高耐受性和更多机会为患者带来有意义的临床益处的靶向药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224657a24604bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224657a24604bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4563","LENZ","MRSN"],"gpt_icon":0},{"id":"2511052180","title":"Mersana Therapeutics, Inc.盘中异动 股价大跌5.01%报0.613美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511052180","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511052180?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:16","pubTimestamp":1739459793,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时16分,Mersana Therapeutics, Inc.股票出现波动,股价大幅跳水5.01%。Mersana Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.02%。Mersana Therapeutics, Inc.公司简介:梅莎娜制药有限公司是一家临床阶段的生物制药公司,利用其差异化和专有的 ADC 平台来开发具有更高耐受性和更多机会为患者带来有意义的临床益处的靶向药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021323163498843551&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021323163498843551&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","MRSN","LENZ","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mersana.com","stockEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":2.2831},{"period":"3month","weight":3.0726},{"period":"6month","weight":1.879},{"period":"1year","weight":-0.5211},{"period":"ytd","weight":-0.2231}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Mersana Therapeutics, Inc.于2002年2月以名称Nanopharma Corp.在特拉华州注册成立。2005年11月,他们更名为Mersana Therapeutics,Inc.。该公司是一家临床阶段的生物制药公司,专注于开发抗体药物偶联物,或ADC,为有重大未满足需求的癌症患者提供具有临床意义的益处。该公司利用ADC领域20年的行业学习,开发专有技术,使设计ADC相对于现有ADC疗法具有更好的疗效、安全性和耐受性。此外,公司与Takeda Pharmaceutical Company Limited或武田建立战略合作关系,据此公司获得了XMT-1522在美国和加拿大以外地区的权利。该公司还与武田和默沙东 KGaA建立了战略研发合作伙伴关系,用于针对合作伙伴基于其Dolaflexin平台选择的有限数量的目标开发和商业化额外的ADC候选产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.054779},{"month":2,"riseRate":0.5,"avgChangeRate":0.134625},{"month":3,"riseRate":0,"avgChangeRate":-0.187861},{"month":4,"riseRate":0.5,"avgChangeRate":0.056403},{"month":5,"riseRate":0.375,"avgChangeRate":0.215196},{"month":6,"riseRate":0.25,"avgChangeRate":-0.085605},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.150945},{"month":8,"riseRate":0.555556,"avgChangeRate":0.059378},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.078098},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.008583},{"month":11,"riseRate":0.666667,"avgChangeRate":0.402507},{"month":12,"riseRate":0.444444,"avgChangeRate":0.001752}],"exchange":"NASDAQ","name":"Mersana Therapeutics Inc.","nameEN":"Mersana Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mersana Therapeutics Inc.(MRSN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Mersana Therapeutics Inc.(MRSN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Mersana Therapeutics Inc.,MRSN,Mersana Therapeutics Inc.股票,Mersana Therapeutics Inc.股票老虎,Mersana Therapeutics Inc.股票老虎国际,Mersana Therapeutics Inc.行情,Mersana Therapeutics Inc.股票行情,Mersana Therapeutics Inc.股价,Mersana Therapeutics Inc.股市,Mersana Therapeutics Inc.股票价格,Mersana Therapeutics Inc.股票交易,Mersana Therapeutics Inc.股票购买,Mersana Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mersana Therapeutics Inc.(MRSN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Mersana Therapeutics Inc.(MRSN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}